Abstract 1497P
Background
Resuscitation decisions in cancer patients continue to challenge Healthcare Professionals (HCPs) and often do not take place until clinical deterioration, risking futile Cardiopulmonary Resuscitation (CPR) attempts. This research investigated outcomes of In-Hospital Cardiopulmonary Arrest (IHCA) in advanced cancer within an NHS Trust in the UK, alongside viewpoints of HCPs.
Methods
This mixed-methods study comprised two components. Retrospective data analysis examined IHCA outcomes in patients with advanced cancer in Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH) between 2012-2022. Main outcomes included rate of Return of Spontaneous Circulation (ROSC) and survival to discharge. Other outcomes were median overall and post-discharge survival. A survey was distributed to senior HCPs in Acute Medicine (AM), Emergency Medicine (EM) and Oncology, to establish perceptions of CPR success in advanced cancer, and gather current opinion on issues surrounding resuscitation in this context.
Results
Among 83 patients, rate of ROSC was 33.7% and 9.6% survived to discharge. Among survivors, median overall survival was 2 days, and post-discharge survival 391 days. 92 HCPs responded to the survey. The mean likelihood of a patient with advanced cancer achieving ROSC was estimated at 13.4%. Oncologists were ranked the most appropriate HCP to discuss resuscitation, and outpatient clinic appointments the most suitable place. From analysis of text comments, important themes were (1) Place, person and timing, (2) Individualised decision-making, and (3) Improving patient understanding.
Conclusions
Survival following CPR is poor in advanced cancer, and fewer than 10% patients in this study gained any meaningful survival benefit. A collective approach is needed from HCPs to integrate personalised discussions about future care and resuscitation into routine cancer management. These should begin early rather than at a time of crisis, with someone the patient trusts. Blanket decisions are not suitable for any patient and cannot supersede clinical judgement alongside assessment of patient priorities and values.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Newcastle Hospitals Charity.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10